Nexalin’s Neurostimulation Tech Shows Strong Anxiety, Depression Results in Pilot Trials
Event summary
- Nexalin’s DIFS™ 15 mA 77.5 Hz treatment platform showed 77.8% anxiety response rate in pilot trials.
- Depressive symptom improvement included a 9.90-point decrease in HAMD scores by Session 20.
- No serious adverse events, seizures, or manic/hypomanic switches were reported.
- Abstracts accepted for presentation at the 2026 NYC Neuromodulation Conference.
- Company preparing for global commercial initiatives, including a potential product launch in Brazil.
The big picture
Nexalin’s acceptance of two clinical abstracts at the 2026 NYC Neuromodulation Conference underscores the growing scientific viability of its non-invasive neurostimulation platform. The company’s focus on deep-brain frequency-based stimulation positions it uniquely in the competitive neuromodulation field, particularly as it prepares for commercial launches in key markets like Brazil. The durable benefits observed in anxiety, depression, and insomnia outcomes highlight the potential for a differentiated approach in addressing neuropsychiatric disorders.
What we're watching
- Clinical Validation
- Whether Nexalin can replicate these pilot trial results in larger, randomized, or controlled clinical studies.
- Regulatory Pathway
- The pace at which Nexalin advances its FDA De Novo regulatory pathway for broader commercialization.
- Market Differentiation
- How Nexalin’s proprietary high-power frequency-based stimulation differentiates it from existing neurostimulation technologies.
Related topics